Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 2/20 | 0.51 |
| ▸ | LGALS8 | O00214 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.39 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893622 | 1.00 | FGF1 (0.51) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL7533461 | 0.91 | LGALS8 (0.57) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL7533468 | 0.91 | LGALS8 (0.57) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL28577159 | 0.84 | LGALS8 (0.47) | FGF1LGALS8F10 | |
| SCHEMBL25505005 | 0.84 | FGF1 (0.53) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL25504956 | 0.84 | FGF1 (0.53) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL7121030 | 0.83 | LGALS8 (0.47) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL7121026 | 0.83 | LGALS8 (0.47) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL30099086 | 0.81 | CA2 (0.43) | FGF1LGALS8CA2LGALS3MAPT | |
| SCHEMBL19594012 | 0.80 | FGF1 (0.51) | FGF1LGALS8F10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414076-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-08-19 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | FGF1 3877/4885LGALS8 887/4885CA1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.